Chartwell Investment Partners LLC Buys New Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Chartwell Investment Partners LLC purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 107,550 shares of the company’s stock, valued at approximately $535,000.

A number of other large investors have also made changes to their positions in AQST. Vanguard Group Inc. increased its holdings in shares of Aquestive Therapeutics by 71.7% during the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after acquiring an additional 1,353,518 shares in the last quarter. Blue Owl Capital Holdings LP increased its stake in Aquestive Therapeutics by 30.3% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after purchasing an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Aquestive Therapeutics in the second quarter worth $594,000. Deerfield Management Company L.P. Series C acquired a new stake in shares of Aquestive Therapeutics during the second quarter worth $380,000. Finally, Rhumbline Advisers purchased a new stake in shares of Aquestive Therapeutics during the second quarter valued at $254,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AQST shares. Leerink Partners raised their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Wednesday, November 6th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus target price of $9.80.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $4.83 on Thursday. The business’s 50-day moving average is $4.98 and its two-hundred day moving average is $3.86. The company has a market capitalization of $440.40 million, a P/E ratio of -10.73 and a beta of 2.82. Aquestive Therapeutics, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter last year, the business posted ($0.03) earnings per share. Analysts forecast that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.